Evidence map›Paper›PMID 31120925›Full record

ArticlePloS one2019

Computational study on new natural compound agonists of stimulator of interferon genes (STING).

Sheng Zhong, Weihang Li, Yang Bai, Bo Wu, Xinhui Wang, Shanshan Jiang, Yingjing Zhao, Jiaxin Ren, Hui Li, Rihua Jin

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 60 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. The Many Ways to Deal with STING.International journal of molecular sciences · 2023
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Molecular Dynamics Simulations Reveal the Modulated Mechanism of STING Conformation.Interdisciplinary sciences, computational life sciences · 2021
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Sheng ZhongDepartment of Neurosurgery, the First Hospital of Jilin University, Changchun, China.
Weihang LiClinical College, Jilin University, Changchun, China.
Yang BaiDepartment of Neurosurgery, the First Hospital of Jilin University, Changchun, China.
Bo WuDepartment of Orthopedics, the First Hospital of Jilin University, Changchun, China.
Xinhui WangDepartment of Oncology, the First Hospital of Jilin University, Changchun, China.
Shanshan JiangCollege of pharmacy, Jilin University, Changchun, China.
Yingjing ZhaoClinical College, Jilin University, Changchun, China.
Jiaxin RenClinical College, Jilin University, Changchun, China.
Hui LiClinical College, Jilin University, Changchun, China.
Rihua JinDepartment of Neurosurgery, the First Hospital of Jilin University, Changchun, China.ORCID 0000-0001-8211-958X
Jilin University · CNBrigham and Women's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aimed to screen lead compounds and medication candidates from drug library (ZINC database) which has potential agonist effect targeting STING protein. METHODS AND MATERIALS: A series of computer-aided virtual screening techniques were utilized to identify potential agonists of STING. Structure-based screening using Libdock was carried out followed by ADME (absorption, distribution, metabolism, excretion) and toxicity prediction. Molecular docking was performed to demonstrate the binding affinity and mechanism between ligands and STING dimers. Molecular dynamic simulation was utilized to evaluate the stability of ligand-receptor complex. Finally, animal experiment was conducted to validate the effectiveness of selected compounds.

resultsThree novel natural compounds 1,2,3 (ZINC000015149223, ZINC000011616633 and ZINC000001577210, respectively) from the ZINC15 database were found binding to STING with more favorable interaction energy. Also, they were predicted with less ames mutagenicity, rodent carcinogenicity, non-developmental toxic potential and tolerant with cytochrome P450 2D6 (CYP2D6). The ligand chemical structure analysis showed the three compounds were inborn axisymmetric, such chemical structures account for combining and activating process of STING protein dimers. The dynamic simulation analysis demonstrated that ZINC000015149223-, ZINC000011616633- and ZINC000001577210-STING dimer complex had more favorable potential energy compared with amidobenzimidazole (ABZI) and they can exist in natural environments stably. Animal experiments also demonstrated that these three compounds could suppress tumor growth.

conclusionThis study demonstrates that ZINC000015149223, ZINC000011616633 and ZINC000001577210 are potential agonists targeting STING protein. These compounds are safe drug candidates and have a great significance in STING agonists development.

Indexed as

AnimalsComputational BiologyDrug DesignDrug Evaluation, PreclinicalHumansLigandsMembrane ProteinsMiceMice, NudeMolecular Docking SimulationMolecular Dynamics SimulationProtein BindingSTING ProteinStructure-Activity RelationshipLigandsMembrane ProteinsSTING1 protein, humanSTING Protein

Identifiers

PMID31120925
PMCPMC6532845
OpenAlexW2946632890

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.